Table 1:
Baseline s100A8/A9, Demographic and Medical Variables by Treatment Group
| Variable | CBT (n=41) | RT (n=38) | HE (n=44) | Total (n=123) | Statistic | p |
|---|---|---|---|---|---|---|
| Age (years), 28–77 | 54.54(9.48) | 54.39(10.68) | 55.43(8.99) | 54.81(9.63) | F(2, 120)=0.142 | 0.868 |
| Surgery to baseline (days) | 34.51 (22.21) | 34.55(16.49) | 35.18(17.15) | 34.76(18.65) | F(2, 120)=0.017 | 0.983 |
| Race/Ethnicity | X2(6)=5.494 | 0.482 | ||||
| Non-Hispanic White | 20(48.78%) | 17(44.74%) | 23(52.27%) | 60(48.78%) | ||
| Hispanic | 13(31.71%) | 18(47.37%) | 18(40.91%) | 49(39.84%) | ||
| African American | 4(9.76%) | 1(2.63%) | 2(4.55%) | 7(5.69%) | ||
| Other | 4(9.76%) | 2(5.26%) | 1(2.27%) | 7(5.69%) | ||
| BMI | 26.51(5.56) | 27.04(4.98) | 26.91(5.96) | 26.81(5.51) | F(2, 107)=0.088 | 0.916 |
| Income (thousands) | 102.58(56.16) | 92.59(59.61) | 125.23(84.10) | 107.60(69.25) | F(2, 120)=2.486 | 0.088 |
| Education (years) | 15.98(2.53) | 15.11(3.04) | 15.18(2.99) | 15.42(2.87) | F(2, 120)=1.154 | 0.319 |
| Married/partnered | 29(70.73%) | 24(63.16%) | 28(63.64%) | 81(65.85%) | X2(2)=0.653 | 0.721 |
| Employed | 31(75.61%) | 26(68.42%) | 29(65.91%) | 86(69.92%) | X2(2)=1.008 | 0.604 |
| Stage | X2(6)=7.269 | 0.297 | ||||
| 0 | 9(21.95%) | 7(18.42%) | 6(13.64%) | 22(17.89%) | ||
| I | 24(58.54%) | 15(39.47%) | 24(54.55%) | 63(51.22%) | ||
| II | 7(17.07%) | 14(36.84%) | 10(22.73%) | 31(25.20%) | ||
| III | 1(2.44%) | 2(5.26%) | 4(9.09%) | 7(5.69%) | ||
| Positive Nodes | 4(9.76%) | 8(21.05%) | 13(29.55%) | 25(20.33%) | X2(2)=4.923 | 0.085 |
| Hormonal Status | ||||||
| Her2 neu | 6(14.63%) | 2(5.26%) | 4(9.09%) | 12(9.76%) | X2(2)=1.832 | 0.400 |
| ER Positive | 34(82.93%) | 28(73.68%) | 33(75.00%) | 95(77.24%) | X2(2)=0.689 | 0.708 |
| PR Positive | 28(68.29%) | 26(68.42%) | 31(70.45%) | 85(69.11%) | X2(2)=0.179 | 0.915 |
| ER or PR Positive | 32(78.05%) | 27(71.05%) | 32(72.73%) | 91(73.98%) | X2(2)=0.282 | 0.868 |
| Surgical Procedure | X2(2)=0.458 | 0.785 | ||||
| Lumpectomy | 20(48.78%) | 18(47.37%) | 24(54.55%) | 62(50.41%) | ||
| Mastectomy | 21(51.22%) | 20(52.63%) | 20(45.45%) | 61(49.59%) | ||
| Adjuvant treatment | 33(80.49%) | 31(81.58%) | 39(88.64%) | 103(83.74%) | X2(2)=2.635 | 0.268 |
| Chemotherapy | 11(26.83%) | 17(44.74%) | 15(34.09%) | 43(34.96%) | X2(2)=2.804 | 0.246 |
| Radiation | 17(41.46%) | 13(34.21%) | 27(61.36%) | 57(46.34%) | X2(2)=5.860 | 0.053 |
| Antihormonal Therapy | 32(78.05%) | 23(60.53%) | 34(77.27%) | 89(72.36%) | X2(2)=2.917 | 0.233 |
| Session Attendance | 4.25(1.25) | 4.09(1.36) | 4.56(0.76) | 4.30(1.16) | F(2, 98)=1.868 | 0.253 |
| Ln s100A8/A9 | 8.17(0.71) | 8.37(0.88) | 7.65(0.77) | F(2, 120)=9.16 | <0.001 |